Lacerol Hta Retard (Diltiazem Hydrochloride)

Diltiazem hydrochloride blocks L‑type calcium channels in cardiac and vascular smooth muscle cells. This action reduces calcium entry, leading to vasodilation of peripheral arteries, decreased myocardial contractility, and slowed atrioventricular nodal conduction. The combined effect lowers systemic blood pressure and reduces the oxygen demand of the heart, which alleviates angina.

The specific dose of Lacerol Hta Retard is determined by the prescribing healthcare professional based on the individual’s medical condition, response to therapy, and other factors. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Diltiazem hydrochloride is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are no adequate human studies. It should be used during pregnancy only if clearly needed. Limited data are available for breastfeeding; the decision to continue should be made by the prescriber after weighing benefits and potential risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lacerol Hta Retard, as a calcium channel blocker, offers a distinct mechanism compared with ACE inhibitors, ARBs, or beta‑blockers. It is particularly useful in patients who need both blood‑pressure control and anti‑anginal effects. Compared with non‑dihydropyridine calcium blockers, diltiazem provides moderate vasodilation with less peripheral edema, making it a balanced choice for many cardiovascular profiles.

Lacerol Hta Retard should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the tablets away from excessive heat and humidity to maintain stability and potency throughout the shelf life.

Lacerol Hta Retard is taken orally, usually as a modified‑release tablet. It should be swallowed whole with a glass of water and not chewed or crushed, to ensure the intended release profile and therapeutic effect.

The most serious risks include severe hypotension, marked bradycardia, heart block, and rare cases of hepatic dysfunction or severe allergic reactions. Patients should be monitored for signs of these events, especially when initiating therapy or adjusting the dose, and seek immediate medical attention if they occur.

Lacerol Hta Retard is contraindicated in patients with known hypersensitivity to diltiazem or other calcium channel blockers, those with severe hypotension, advanced heart block without a pacemaker, and certain forms of sick sinus syndrome. Caution is also advised for individuals with severe hepatic impairment or those taking interacting medications that could elevate diltiazem levels.